Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the
formation of an Expert Oncology Panel to provide guidance on
research and development strategies for the Company’s portfolio of
novel oncology therapies.
Inaugural members of Synta’s Expert Oncology Panel include:
- David E. Avigan, M.D. - Chief Section
of Hematological Malignancies and Bone Marrow Transplantation, Beth
Israel Deaconess Medical Center Associate Professor, Medicine,
Harvard Medical School
- Bruce Allan Chabner, M.D. - Director of
Clinical Research, Cancer Center Massachusetts General Hospital
Cancer Center
- Jeffrey A. Engelman, M.D., Ph.D. -
Director, Center for Thoracic Cancers Massachusetts General
Hospital Cancer Center, Associate Professor of Medicine Harvard
Medical School
- F. Stephen Hodi, Jr., M.D. - Director,
Melanoma Center Director, Center for
Immuno-Oncology, Associate Professor of Medicine Harvard
Medical School, Dana Farber Cancer Institute
- Martin J. Murphy, D. MedSc, Ph.D.,
FASCO - Chairman and Chief Executive Officer AlphaMed Consulting,
Inc.
- Neil Lee Spector, M.D. - Associate
Professor of Medicine, Sandra Coates Associate Professor, Associate
Professor of Pharmacology & Cancer Biology, Member of the Duke
Cancer Institute
“It is our pleasure to welcome a group of world-renowned
physicians and scientists to our newly formed Expert Oncology
Panel,” said Chen Schor, President and Chief Executive Officer of
Synta. “We expect that this panel will lend important perspective
in translating the breadth of emerging preclinical and clinical
data with ganetespib into well designed clinical studies aimed at
providing meaningful clinical benefits to cancer patients in
selected indications. The advice of the panel will also be
important in shaping our HDC program strategy as we move towards
the clinic with the first candidate from this program, STA-12-8666,
and consider additional payloads for development. This
distinguished expert panel, together with our newly appointed Chief
Scientific Officer, Dr. Alan Rigby, is taking Synta one step
further in our mission to discover, develop and commercialize
oncology medicines that change cancer patients lives.”
Dr. Avigan is Professor, Department of Medicine, Harvard Medical
School, Chief, Hematological Malignancy and Bone Marrow Transplant
section at Beth Israel Deaconess Medical Center and a co-Clinical
Leader of the Leukemia Program at the Dana Farber Harvard Cancer
Center. He leads a translational research program for hematological
malignancies with a focus on vaccine therapy, tumor immunology, and
stem cell biology with a strong track record for clinical
translation of biologic based treatments. Dr. Avigan earned his
M.D. from Yale University School of Medicine, completed his
residency at Columbia Presbyterian Medical Center in Internal
Medicine, and his fellowship at Memorial Sloan-Kettering Cancer
Center in Hematology/Oncology.
Dr. Chabner is the Clinical Director, Emeritus, and Paul G.
Allen Scholar at the Massachusetts General Hospital Cancer Center.
During his career at the National Cancer Institute (NCI), he served
as a Senior Investigator in the Laboratory of Chemical
Pharmacology, Chief of the Clinical Pharmacology Branch, Director
of the Clinical Oncology Program, and Director of the Division of
Cancer Treatment. At the NCI, he maintained an active laboratory
program in cancer pharmacology, and led the development of Taxol®.
His research contributed significantly to the development of high
dose chemotherapy regimens, and to standard therapies for lymphoma.
Dr. Chabner is the Editor in Chief for The Oncologist and serves on
the executive advisory boards for some of the industry's leading
innovators in drug development. In 2006, Dr. Chabner received a
presidential appointment to the National Cancer Advisory Board at
the NCI, which he chaired from 2010 to 2012. Dr. Chabner earned his
M.D. at Harvard Medical School, completed his residency at Brigham
and Women’s Hospital, and his fellowships at the NCI and Yale-New
Haven Hospital.
Dr. Engelman is the Director, Center for Thoracic Cancers
at the Massachusetts General Hospital Cancer Center and an
Associate Professor of Medicine at the Harvard Medical School. The
overarching aim of research in the Engelman laboratory at Mass
General is to develop new and more effective therapeutic strategies
for the treatment of cancer, with a particular emphasis on lung
cancer. Dr. Engelman is board certified in medical oncology and
earned his M.D. and Ph.D. from the Albert Einstein College of
Medicine. He completed his residency at Brigham and Women’s
Hospital and Fellowship at the Dana Farber Cancer Institute and
Massachusetts General Hospital combined program.
Dr. Hodi is the Director of the Melanoma Center and the Center
for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer
Center and Assistant Professor of Medicine at Harvard Medical
School. He received his M.D. degree from Cornell University Medical
College in 1992. Dr. Hodi competed his postdoctoral training in
Internal Medicine at the Hospital of the University of
Pennsylvania, and Medical Oncology training at Dana-Farber Cancer
Institute where he joined the faculty in 1995. His research focuses
on gene therapy, the development of immune therapies, and first
into human studies for malignant melanoma. Dr. Hodi is a member of
the National Comprehensive Cancer Network, the American Society of
Clinical Oncology, the Eastern Cooperative Oncology Group Melanoma
Committee, the International Society for the Biological Therapy of
Cancer, and a founding member of the Society for Melanoma
Research.
Dr. Murphy is the Founding Chairman and Chief
Executive Officer of AlphaMed Consulting, Inc., a consultancy that
provides strategic support for academic cancer centers and cancer
drug development programs of global pharmaceutical and
biotechnology companies. He is the founding Executive Editor of
three journals: The Oncologist, Stem Cells and of Stem Cells
Translational Medicine. Dr. Murphy was founding Chief Executive
Officer of Hipple Cancer Research Center and an NIH principal
investigator who merited more than $25 million in competitive NIH
grants. He is Co-founder of the Society for Translational
Oncology, a member of the Scientific Advisory Board
of Hatteras Venture Partners, a charter member of
the International Advisory Board of Amsterdam’s VU
University Medical Imaging Center, a charter member of Queen's
University-Belfast School of Medicine International Review Board,
Chairman Emeritus of the Conquer Cancer Foundation of
the American Society of Clinical Oncology (ASCO),
convener of ACT-China, and Steering Committee Member and
Senior Consultant of the Chinese Society of Clinical Oncology.
He is also a member of the National Cancer Policy
Forum of the National Academy of Medicine of
the United States National Academy of Sciences, a director of
the Foundation for the National Institutes of Health, a member
of the Board of Visitors of the UNC Lineberger Comprehensive
Cancer Center, a member of the Board of Advisors of the H. Lee
Moffitt Cancer Center & Research Institute and a charter
member and vice chairman of C-Change, founded by former
President George H.W. Bush and former First Lady Barbara Bush. Dr.
Murphy is a Fellow of the American Society of Clinical Oncology and
is Founding Chief Executive Officer of the non-profit CEO
Roundtable on Cancer at the request of the Forty-First
President George H.W. Bush.
Dr. Spector is the Sandra Coates Chair Breast Cancer Research at
the Duke University Medical Center, Leader of the Developmental
Therapeutics Program, Duke Cancer Institute, and currently serves
as Scientific Advisor to Synta. Prior to joining Duke, Dr. Spector
served as Director of GlaxoSmithKline’s Exploratory Medical
Sciences in Oncology, where he successfully guided the development
of Tykerb® (lapatinib) and Arranon® (nelarabine) from initial
preclinical studies through clinical development and eventual FDA
approval. Dr. Spector is board-certified in Hematology, Medical
Oncology and Internal Medicine and earned his M.D. at the
University of Medicine and Dentistry of New Jersey. He completed
his residency in Internal Medicine at Parkland Memorial Hospital,
University of Texas, Southwestern Medical Center and in Medical
Oncology/Hematology at the Dana Farber Cancer Institute and
Massachusetts General Hospital combined program.
About Synta Pharmaceuticals
Synta Pharmaceuticals Corp. is an innovative, agile
biopharmaceutical company focused on research, development and
commercialization of novel oncology medicines that have the
potential to change the lives of cancer patients. Synta’s lead
oncology drug candidate, ganetespib, a novel heat shock protein 90
(Hsp90) inhibitor, is currently being evaluated in several clinical
trials including the pivotal GALAXY-2 Phase 3 trial in non-small
cell lung cancer. Building on its extensive expertise in the
science of Hsp90, Synta also has a novel proprietary Hsp90
inhibitor Drug Conjugate (HDC) small molecule drug development
program. IND enabling studies have commenced for the first clinical
candidate from the HDC program, STA-12-8666, and preclinical
evaluation of additional HDC candidates is ongoing. For more
information, please visit www.syntapharma.com.
Safe Harbor Statement
This media release may contain forward-looking statements
about Synta Pharmaceuticals Corp. Such forward-looking
statements can be identified by the use of forward-looking
terminology such as "will", "would", "should", "expects",
"anticipates", "intends", "plans", "believes", "may", "estimates",
"predicts", "projects", or similar expressions intended to identify
forward-looking statements. Such statements reflect Synta’s current
views with respect to future events and are based on assumptions
and subject to risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
such forward-looking statements, including those described in "Risk
Factors" of our Form 10-K for the year ended December 31,
2014 as filed with the Securities and Exchange
Commission. Synta undertakes no obligation to publicly update
forward-looking statements, whether because of new information,
future events or otherwise, except as required by law.
Tykerb® and Arranon® are registered trademarks of the
GlaxoSmithKline group of companies.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151008005630/en/
Investors:Synta Pharmaceuticals Corp.Daniel Cole,
781-541-7250dcole@syntapharma.comorArgot PartnersAndrea Rabney,
212-600-1494andrea@argotpartners.comorMedia:Argot
PartnersEliza Schleifstein, 917-763-8106eliza@argotpartners.com
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Synta Pharmaceuticals Corp. (MM) (NASDAQ:SNTA)
Storico
Da Nov 2023 a Nov 2024
